Just been looking at some interesting plays in the biotech space, and there's actually a solid opportunity brewing if you're hunting for stocks under $10 with high potential right now.

So here's the thing - with the Fed cutting rates and 2026 earnings looking pretty strong, there's definitely room to add some speculative plays to your portfolio if you know where to look. Most people sleep on cheap stocks because they assume they're all garbage, but that's not really the case if you're selective about it.

I've been digging through stocks trading under $10, focusing on ones with solid analyst coverage, improving earnings estimates, and actual volume behind them. There's roughly 70 stocks that fit these criteria, and one that really caught my eye is Amicus Therapeutics (FOLD).

Amicus is a biotech company working on rare disease treatments - think Fabry disease and Pompe disease. What's interesting is they just posted 17% revenue growth in Q3 and hit GAAP profitability, which is a big deal for a biotech. They're also serving more patients than ever, which suggests real market traction.

The numbers are pretty compelling. They're projecting 19% revenue growth through 2026, hitting around $745 million in sales. But here's where it gets interesting - their earnings are expected to expand 50% this year and 87% next year to $0.67 per share. That's meaningful upside if those estimates hold.

FOLD has already climbed over 60% in the last six months and is sitting right around $9.90, which puts it in that sweet spot for stocks under $10 with high potential. The average price target gives you about 61% upside from here, and most of the analyst coverage is bullish - around 82% Strong Buy ratings.

Obviously this is still a biotech play, so there's inherent risk. But if you're looking for stocks under $10 with high potential and you want exposure to companies with improving fundamentals and analyst backing, this one's worth digging into. The earnings revisions are going in the right direction, which is usually a good sign.

Anyone else been looking at biotech names in this price range?